AlphAIalphai — Financial news for AI agents
manilatimes.netJUN 52 min read$DBVT

DBV Technologies to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

DBV Technologies said CEO Daniel Tassé will take part in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026, at 9:20 a.m. ET in Miami. The company will webcast the session and provide a replay for 90 days on its investor events page.

Original reporting
manilatimes.net
Published Jun 5, 2026, 9:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 5, 2026, 9:34 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
DBV Technologies to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference — source image
Source · manilatimes.net
Decision brief

The 30-second read

$DBVTNeutralLow
01

Why it matters

This is an investor-visibility event; without new clinical or financial information, it mainly affects short-term sentiment and positioning.

02

Market read

Expect modest event-driven attention; meaningful trading impact would require new VIASKIN trial or guidance disclosures not present in this announcement.

03

What to watch

Traders should watch for any subsequent press release or transcript that includes trial readouts, enrollment updates, or regulatory interactions—those would be the real drivers.

Relevance 5/10Novelty 2/10Timing: Ahead of the June 9, 2026 9:20 AM ET fireside chat

Background

DBV Technologies is a late-stage biopharmaceutical company developing VIASKIN® epicutaneous immunotherapy patches for food allergies.

Company-level read

Ticker impact

$DBVTNeutralHigh confidence
Context

DBV Technologies’ CEO will present at Goldman’s healthcare conference, potentially shaping near-term sentiment and expectations for VIASKIN updates.

Expected impact

Low, likely limited to event-driven attention unless accompanied by new VIASKIN trial or guidance details.

Evidence & confidence

The article only announces a fireside chat and webcast access; no new clinical results, timelines, or financial guidance are provided.

Market effects

Sector

Adds incremental visibility for late-stage food-allergy EPIT developers; no direct read-across catalysts stated.

Regional

Minimal; primarily US investor-relations visibility despite France/Euronext listing.

Global

Low; conference event is not tied to a global regulatory or trial milestone in the article.

Counterpoint

What could challenge this read

If the fireside chat contains no new data, any pre-event positioning may fade quickly after the event.

Key entities

  • company
    DBV Technologies

    Late-stage biopharmaceutical company focused on VIASKIN® patch-based epicutaneous immunotherapy for food allergies.

  • person
    Daniel Tassé

    CEO scheduled to participate in a Goldman Sachs healthcare conference fireside chat.

  • event
    Goldman Sachs 47th Annual Global Healthcare Conference

    Conference where the CEO fireside chat is scheduled for June 9, 2026 at 9:20 AM ET.

Read at source← All news

Related articles

JUL 30
$DBVTMedAI 8/10

DBV Technologies S.A.: DBV Technologies Announces Sale of Approximately $50 Million of ADSs Through Its At-The-Market (ATM) Program on Nasdaq

Châtillon, France, July 30, 2026 DBV Technologies Announces Sale of Approximately $50 Million of ADSs Through Its At-The-Market (ATM) Program on Nasdaq DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Capital Market: DBVT) (the "Company"), a late-stage biopharmaceutical company, today announced that, pursuant to the Company's At-The-Market Program established on September 1, 2025 and included in a new registration statement and accompanying prospectus filed on July 27, 2026, (the...

finanznachrichten.de4 min
JUL 17
$DBVTMedAI 8/10

DBV Technologies S.A.: DBV Technologies Files At-The-Market (ATM) Prospectus for Up to $150 Million of Sales

DBV Technologies said it filed an automatically effective SEC Form S-3ASR shelf registration to refresh its at-the-market program for sales of up to $150 million of American Depositary Shares. The ADSs represent five ordinary shares and the program is under a Sept. 5, 2025 sales agreement with Citizens JMP Securities. Net proceeds would fund manufacturing expansion, BLAs, Viaskin Peanut launch prep, development, and working capital.

finanznachrichten.de2 min
JUL 16
$DBVTMed

DBV Technologies S.A. (DBVT): Results of Operations and Financial Condition

DBV Technologies S.A. (DBVT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 d156695dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Press Release Châtillon, France, July 16, 2026 DBV Technologies Reports Second Quarter and Half-Year 2026 Financial Results and Business Update • Continued productive engagement with the FDA in support of the BLA for the VI

SEC EDGAR 8-K6 min
JUL 16
$DBVTMedAI 8/10

DBV Technologies S.A.: DBV Technologies Reports Second Quarter and Half-Year 2026 Financial Results and Business Update

DBV Technologies reported Q2 and half-year 2026 results. It said FDA engagement for the VIASKIN Peanut Patch BLA for children ages 4-7 continues, with BLA submission expected in Q3 2026 and no additional data requested. Cash and cash equivalents were $174.9 million at June 30, 2026, funding into Q3 2027. Net loss was $98.0 million for six months.

finanznachrichten.de6 min
JUN 29
$DBVTMed

DBV Technologies S.A.: DBV Technologies Provides BLA Submission Update for the VIASKIN Peanut Patch in Children Aged 4 through 7 Years; Working Collaboratively with FDA to Optimize Review Process in P

DBV Technologies said it has been in iterative discussions with the FDA ahead of its BLA for the VIASKIN Peanut Patch in children aged 4–7. The FDA has not requested additional data, and DBV plans to incorporate feedback and submit the BLA in Q3 2026. A conference call is scheduled for June 29, 2026.

finanznachrichten.de3 min